Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis

BMC Structural Biology

CN Paramasivan⁴  Mukesh Doble¹  Sulochana Somasundaram³  RS Anand² 

[1] Department of Biotechnology, Indian Institute of Technology - Madras, Chennai 600 036, India;Centre for Biotechnology, Anna University, Chennai 600 025, India;Department of Biotechnology, Sri Venkateswara College of Engineering, Sriperumbudur 602 105, India;Foundation for Innovative New Diagnostics, 16, Avenue de Budé 1202 Geneva, Switzerland

关键词: moxifloxacin;    gatifloxacin;    Fluoroquinolones;    GyrA;    Mycobacterium tuberculosis;    Docking;   

Others  :  1092480
DOI  :  10.1186/1472-6807-11-47

 received in 2011-09-13, accepted in 2011-12-12,  发布年份 2011

【 摘 要 】

Background

Fluoroquinolone resistance is a serious threat in the battle against the treatment of multi drug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). Fluoroquinolone resistant isolates from India had shown to have evolved several mutants in the quinolone resistance determining region (QRDR) of DNA gyrase A subunit (GyrA), the target of fluoroquinolone. In view of high prevalence of mutations in the 'hot spot' region, a study on combinatorial drug design was carried out to identify better analogues for the treatment of MDR-TB. The gyrA subunit 'hot spot' region of codons 90, 94 and 95 were modeled into their corresponding protein folds and used as receptors for the docking studies. Further, invitro tests were carried using the parent compounds, namely gatifloxacin and moxifloxacin and correlated with the obtained docking scores.

Results

Molecular docking and in vitro studies correlated well in demonstrating the enhanced activity of moxifloxacin, when compared to gatifloxacin, on ofloxacin sensitive and resistant strains comprising of clinical isolates of MDR-TB. The evolved lead structures targeting against mutant QRDR receptors were guanosine and cholesteryl esters of gatifloxacin and moxifloxacin. They showed consistently high binding affinity values of -10.3 and -10.1 kcal/mol respectively with the target receptors. Of these, the guanosine ester showed highest binding affinity score and its log P value lied within the Lipinski's range indicating that it could have better absorptivity when it is orally administered thereby having an enhanced activity against MTB.

Conclusions

The docking results showed that the addition of the cholesteryl and guanosine esters to the 'DNA gyrase binding' region of gatifloxacin and moxifloxacin enhanced the binding affinity of these parent molecules with the mutant DNA gyrase receptors. Viewing the positive correlation for the docking and in vitro results with the parent compounds, these lead structures could be further evaluated for their in vitro and in vivo activity against MDR-TB.

【 授权许可】

   
2011 Anand et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]World Health Organization: Anti-tuberculosis drug resistance in the world. WHO/TB/97/229
• [2]Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C: The growing burden of Tuberculosis. Global trends and interactions with the HIV Epidemic. Arch intern Med 2003, 163:1009-1021.
• [3]Kantardjieff K, Rupp B: Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr Pharm Des 2004, 10:3195-3211.
• [4]Ginsburg AS, Grosset JH, Bishai WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
• [5]Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H: Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004, 48:780-782.
• [6]Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, Globe M, Iseman MD: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004, 169:1103-1109.
• [7]Hooper CD, Rubinstein E: Quinolone Antimicrobial Agents. ASM Press; 2003.
• [8]Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB: Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. Clin Infect Dis 2010, 51(1):6-14.
• [9]Liu J, Takiff HE, Nikaido H: Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 1996, 178(13):3791-3795.
• [10]Masand VH, Patil KN, Mahajan DT, Jawarkar RD, Nazerruddin GM: 3 D- QSAR studies on xanthone derivatives to understand pharmacological activities as MAO inhibitors. Der Pharma Chemica 2010, 2(5):22-32.
• [11]Schentag J, Domagala J: Structure-activity relationships with the quinolone antibiotics. Res Clin Forums 1985, 7:9-13.
• [12]Sulochana S, Rahman R, Paramasivan CN: In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005, 1(2):81-85.
• [13]Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25:3389-3402.
• [14]Sulochana S, Sujatha N, Paramasivan CN, Suganthi C, Narayanan PR: Analysis of Fluoroquinolone Resistance in Clinical isolates of Mycobacterium tuberculosis from India. J Chemother 2007, 19:166-171.
• [15]Trott O, Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010, 31:455-461.
• [16]Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
• [17]ACD/ChemSketch Freeware, version 10.00 [http://www.acdlabs.com] webciteAdvanced Chemistry Development, Inc., Toronto, ON, Canada; 2006.
• [18]Schuettelkopf AW, Van Aalten DMF: PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Cryst 2004, D60:1355-1363.
• [19]Piton J, Petrella S, Delarue M, André-Leroux G, Jarlier V, Aubry A, Mayer C: Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 2010, 5(8):e12245.
• [20]Sulochana S, Mitchison DA, Kubendiren G, Venkatesan P, Paramasivan CN: Bactericidal Activity of Moxifloxacin on Exponential and Stationary Phase cultures of Mycobacterium tuberculosis. J Chemother 2009, 21(2):127-134.
• [21]Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA: Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49(2):627-631.
• [22]Cynamon MH, Sklaney M: Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003, 47(8):2442-2444.
• [23]Emami S, Shafiee A, Foroumadi A: Quinolones: Recent Structural and Clinical Developments. Iranian Journal of Pharmaceutical Research 2005, 3:123-136.
• [24][http://www.molegro.com/index.php] webcite
• [25][http://www.accelrys.com/products/discovery-studio/] webcite
• [26]Kitchen DB, Decornez H, Furr JR, Bajorath J: Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat Rev Drug Discov 2004, 3:935-949.
• [27]Rattan A, Kalia A, Ahmad N: Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 1998, 4(2):195-209.
• [28]Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, Salazar L, Bloom BR, Jacobs WR Jr: Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996, 93(1):362-366.
• [29]Guzman CP, Vargas MH, Quinonez F, Brazavilvazo N, Aquilar A: A Cholesterol-Rich Diet Accelerates Bacteriologic Sterilization in Pulmonary Tuberculosis. CHEST 2005, 127:643-651.
• [30]Brzostek A, Dziadek B, Rumijowska-Galewicz A, Pawelczyk J, Dziadek J: Cholesterol oxidase is required for virulence of Mycobacterium tuberculosis. FEMS Microbiology Letters 2007, 275(1):106-112.
• [31]Muñoz S, Rivas-Santiago B, Enciso JA: Mycobacterium tuberculosis entry into mast cells through cholesterol-rich membrane microdomains. Scand J Immunol 2009, 70(3):256-63.
• [32]Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y: Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm 2004, 285(1-2):23-34.
• [33]Schmalfuß U, Neubert RW, Wohlrab : Modification of drug penetration into human skin using microemulsions. J Control Rel 1997, 46:279-285.
• [34]Simões MF, Valente E, José Rodríguez Gómez M, Anes E, Constantino L: Lipophillic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis. Eur J Pharm Sci 2009, 37(3-4):257-263.
• [35]Crotty S, Cameron C, Andino R: Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002, 80(2):86-95.
• [36]Huang YY, Deng JY, Gu J, Zhang ZP, Maxwell A, Bi LJ, Chen YY, Zhou YF, Yu ZN, Zhang XE: The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). Nucleic Acids Res 2006, 34(19):5650-5659.
• [37]Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA: Moxifloxacin and Gatifloxacin in a new acid model of Persistent Mycobacterium Tuberculosis. J Chemother 2007, 18:65-71.
• [38]Khan HA: Benzene's toxicity: a consolidated short review of human and animal studies. Hum Exp Toxicol 2007, 26(9):677-685.